- Home
- AGMH vs JAGX Comparison
AGMH vs JAGX Comparison
Compare AGMH & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGMH | JAGX |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.2M |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AGMH | JAGX |
|---|---|---|
| Price | $1.09 | $1.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 46.4K | ★ 56.3K |
| Earning Date | 05-13-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,511,000.00 |
| Revenue This Year | N/A | $61.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.07 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.77 | $0.22 |
| 52 Week High | $18.10 | $8.00 |
Technical Indicators
Market Signals| Indicator | AGMH | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 49.46 | 33.54 |
| Support Level | $1.01 | $1.68 |
| Resistance Level | $1.38 | $1.98 |
| Average True Range (ATR) | 0.10 | 0.20 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 47.30 | 0.00 |
Price Performance
Historical ComparisonAbout AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an integrated technology company. The company focuses on blockchain-oriented ASIC chip design, high-end crypto miner production, and fintech technology software services. The company generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.